

REMARKS

The Examiner has delineated the following inventions as being patentably distinct:

- Group I: Claims 1-3 and 11-13, drawn to a peptide derived from the amino acid sequence of human WT1 set forth in SEQ. ID NO: 1 and having activity as an HLA-A26-binding cancer antigen peptide, and pharmaceutical compositions comprising the same;
- Group II: Claims 4-7, drawn to polynucleotides expressing the peptide, and expression vectors and cells comprising the same, and a method of using the same to synthesize the peptide;
- Group III: Claim 8, drawn to an antibody which specifically binds to the peptide;
- Group IV: Claim 9, drawn to an antigen-presenting cell comprising a complex of the peptide and HLA-A26 antigen;
- Group V: Claim 10, drawn to a CL which recognizes a complex between the peptide and HLA-A26 antigen;
- Group VI: Claims 14 and 15, drawn to a complex between the peptide and HLA-A26 antigen;
- Group VII: Claims 16-18 drawn to a pharmaceutical composition comprising a peptide of SEQ. ID NO: 3, or an epitope peptide comprising the peptide, or an expression vector containing a polynucleotide encoding the peptide, or a cell comprising the expression vector, or an antigen-presenting cell comprising a complex of the peptide and HLA-A\*0201 antigen, or a CTL which recognizes the complex; and
- Group VIII: Claims 19 and 20, drawn to a complex of a peptide of SEQ. ID NO: 3 and HLA-A\*0201 antigen.

The Examiner further required the election of a single species. Accordingly, Applicants elect without traverse Group I, Claims 1-3 and 11-13 drawn to a peptide derived from the amino acid sequence WT1 set forth in SEQ. ID NO: 1 and having activity as an HLA-A26 binding cancer antigen peptide, and pharmaceutical composition comprising the same. And for a species, Applicants elect peptide of SEQ. ID NO: 9 for examination purpose also without traverse.

Further, Applicants reserve the right to file divisional applications if so desired on the non-elected subject matter and be accorded the benefit of the filing date of the parent application. Divisional applications filed thereafter should not be subject to double-patenting ground of rejection, 35 USC 121, *In re Joyce*, (Comr. Pats 1957) 115 USPQ 412.

Restriction is only proper if the claims of the restricted groups are independent or patentably distinct and there would be a serious burden placed on the Examiner if restriction is not required (M.P.E.P. § 803).

Applicants make no statement regarding the patentable distinctness of the species, but note that for the restriction to be proper there must be patentable differences.


Applicants submit that the above-identified application is now in condition for examination on the merits, and an early notice of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413-2220  
(OSMMN 06/04)



Paul J. Killos

Registration No. 58,014